Objective  To understand the usage of national medical insurance negotiated drugs (hereinafter referred to as “negotiated drugs”) at Tianjin Second People's Hospital and to provide  references for optimizing and adjusting the hospital's drug catalog.

Methods  A retrospective study was conducted on the usage of negotiated drugs from January 1, 2018 to December 31, 2022 to compare changes in the unit price of drugs, the quantity and amount of sales, the usage frequency (DDDs) and the daily average cost (DDC), etc before and after the negotiation.

Results  Between 2018 and 2022, the varieties of negotiated drugs used in the hospital increased from the original 5 to 24. Among the 13 drugs analyzed for comparison, the unit prices of 11 drugs had been reduced after negotiation, and 7 drugs were included in the medical insurance and outpatient-specific disease payment directory. The average decrease in DDC was 36.43%, and the average increase in DDDs was 1 770.31%. The implementation of this policy had increased the accessibility of medication for patients and significantly increased sales quantity.

Conclusion  The quantity of sales of negotiated drugs significantly increased through reducing the unit price of drugs and including them in the scope of medical insurance payment, etc. These increase the pharmacoeconomic viability of negotiated drugs, effectively reduce the burden on patients, promote rational drug use in hospitals, and improve the access and efficiency of drugs.

1.李娜. 高值药物医保谈判管理模式优化及药品谈判评价探索研究-以癌症药物为例[D]. 南京: 东南大学, 2021.

2.谢金平, 邵蓉. 国家医保谈判药品省级落地管理典型模式研究[J]. 中国卫生经济, 2020, 39(6): 42-46. [Xie JP, Shao R. A study on the typical model of provincial-level landed management of national health insurance negotiated drugs[J]. China Health Economics, 2020, 39(6): 42-46.] DOI: 10.7664/CHE20200610.

3.郭玉娇,罗璨,邹颖. 2015~2019年南京地区37家医院新型口服抗肿瘤药物利用分析[J]. 药物流行病学杂志, 2021, 30(10): 687-694. [Guo YJ, Luo C, Zhou Y. Investigation of clinical application of new oral antitumor drugs used in 37 hospitals in Nanjing during 2015-2019[J]. Chinese Journal of Pharmacoepidemiology, 2021, 30(10): 687-694.] DOI: 10.19960/j.cnki.issn1005-0698.2021.10.009.

4.Chai Y. Impact assessment of the national centralised purchasing pilot policy on pharmaceutical companies and the pharmaceutical industry[D]. Tucson, USA: University of Arizona, 2020.

5.刘苏瑶, 王志庆. 国家组织药品集中采购对南京医科大学附属脑科医院抗精神病药使用影响分析 [J]. 现代药物与临床, 2022, 37(6): 1365-1371. [Liu SY, Wang ZQ. Effects of centralized drug procurement on the use of antipsychotics in The Affiliated Brain Hospital of Nanjing Medical University[J]. Modern Drugs and Clinics, 2022, 37(6): 1365-1371.] DOI: 10.7501/j.issn.1674-5515. 2022.06.036.

6.陈华漫, 陈耀宙, 汪晓琴. 某院高值谈判药品临床应用分析[J]. 临床合理用药杂志, 2022, 15(4): 148-151. [Chen HM, Chen YZ, Wang XQ. Analysis of clinical application of high-value negotiated drugs in a hospital[J]. Journal of Clinical Rational Use of Drugs, 2022, 15(4): 148-151.] DOI: 10.15887/j.cnki.13-1389/r.2022.04.046.

7.张博, 丁锦希, 陈烨, 等. 国家医保谈判药品“双通道”政策动因与实施模式[J]. 世界临床药物, 2021, 42(9): 709-716. [Zhang B, Ding JX, Chen Y, et al. Policy motivation and implementation model of "dual-channel" for negotiated medicines under national health insurance[J]. World Clinical Drugs, 2021, 42(9): 709-716.] DOI: 10.13683/j.wph.2021.09.001.

8.马玉芳, 李雯霞, 杨晓晖, 等. 美国ICER药品价值评估框架分析及思考[J]. 药物流行病学杂志, 2021, 30(7): 441-447. [Ma YF, Li WX, Yang XH, et al. Analysis and reflection on the ICER drug value assessment framework in the United States[J]. China Academic Journal Electronic Publishing House, 2021, 30(7): 441-447.] DOI: 10.19960/j.cnki.issn1005-0698.2021.07.003.

9.中国药学会科技开发中心. 中国医保药品管理改革进展与成效蓝皮书[R]. 北京: 中国药学会, 2021.

10.李洪宇. 山东省药品价格谈判政策实施前后抗肿瘤药物可获得性和可负担性变化的评价研究[D]. 济南: 山东大学, 2021.

11.谭清立,郭润镒,孙慧琳,等. 药品集中带量采购与医保谈判政策的协同作用[J]. 中国药房, 2021, 32(15): 1793-1799. [Tan QL, Guo RY, Sun HL, et al. Synergy of centralized drug volume-based purchasing and medical insurance negotiation policy[J]. China Pharmacy, 2021, 32(15): 1793-1799.] DOI: 10.6039/j.issn.1001-0408.2021.15.01.

12.黄莉莉,王欣,刘慧. 南京地区34家医院2016~2018年国家谈判抗肿瘤药应用分析[J]. 药物流行病学杂志, 2020, 29(10): 687-690. [Huang LL, Wang X, Liu H. Analysis of the utilization of national-negotiation anti-tumor drugs in Nanjing area from 2016 to 2018[J]. Chinese Journal of Pharmacoepidemiology, 2020, 29(10): 687-690.] DOI: 10.19960/j.cnki.issn1005-0698.2020.10.007.

13.李明爽, 刁一凡, 叶建春, 等. 国家谈判靶向抗乳腺癌药物纳入基本医疗保险政策患者惠及研究[J]. 药物流行病学杂志, 2021, 30(6): 398-403, 428. [Li MS, Diao YF, Ye JC, et al. Analysis of how public health insurance coverage of targeted anti-breast cancer medicines through national medicines price negotiation benefited patient[J]. Chinese Journal of Pharmacoepidemiology, 2021, 30(6): 398-403, 428.] DOI: 10.19960/j.cnki.issn1005-0698.2021.06.007.